CDC37 and hepatocellular carcinoma: Sukumaran et al. introduced a rational design strategy to develop peptide-based inhibitors targeting the Hsp90–Cdc37 interaction as a therapeutic avenue in hepatocellular carcinoma.62 A linear hexapeptide derived from a conserved KTGDEK motif was synthesized and modified into a library of pre-cyclic and cyclic peptidomimetics (Fig. 7).